NCT00034983已完成3 期
A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 900
- 主要终点
- Long-term safety and tolerability.
研究概览
简要总结
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
详细描述
The duration of treatment is 1 year.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Long-term safety and tolerability.
时间窗: Duration of treatment
次要结局
- Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences(Duration of treatment)
研究者
相似试验
已完成
3 期
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)Major Depressive DisorderNCT00048594Merck Sharp & Dohme LLC800
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)Major Depressive DisorderNCT00035048Merck Sharp & Dohme LLC540
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive DisorderNCT00035282Merck Sharp & Dohme LLC450
Unknown
2 期
A Study To Evaluate the Safety, Tolerance, Pharmacokinetics/Pharmacodynamics and Efficacy of SYHA1402 Tablets For the Treatment of Patients With Diabetic Peripheral Neuropathy in ChinaDistal Symmetric Polyneuropathy (DSPN)NCT05116111CSPC ZhongQi Pharmaceutical Technology Co., Ltd.135
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive DisorderNCT00035295Merck Sharp & Dohme LLC584